Corneal Epithelial Wound Healing
Conditions
Keywords
epithelial defect, re-epithelialization, reepithelialization, dexpanthenol, trans - PRK, contrallateral study, double-blinded study, prospective study, corneal healing, corneal epithelium healing
Brief summary
The aim of this prospective, contralateral, randomized, double-blind, placebo-controlled study is the evaluation of the performance of a fixed combination of dexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops, in corneal wound healing after trans epithelial photorefractive keratectomy. One eye of each patient, randomly determined, will be assigned to receive artificial tears containing a combination of dexpanthenol-hyaluronic acid (study group) while the fellow eye will receive Placebo / identical combination containing the same ingredients and hyaluronic acid without dexpanthenol (control group). The drops will be applied hourly postoperatively, starting one hour after the surgery. All subjects will be treated until the day of complete reepithelialization or a maximum of 7 days postoperatively. Researchers will compare the epithelialization between the two eyes. The primary endpoint is the time to reepithelialization.The secondary endpoints are the intra-individual differences measured in each eye in terms of epithelial defect size in each visit, subjective evaluation of pain (discomfort) and subjective evaluation of vision.
Interventions
DRUGdexpanthenol and hyaluronic acid preservative-free eye artificial tears eye drops
Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
DRUGPlacebo
Subjects will receive 1 drop of a hyaluronic acid preservative-free eye artificial tears eye drops (HA) as PLACEBO hourly during the day, but at least 12 times a day, until complete reepithelialization. Composition: 1 ml contains Sodium Hyaluronate 0.15 %, Sodium Chloride, Sodium Citrate, Citric Acid, Water for Injections Dosage Form: Single-dose container (0.5 mL)
Sponsors
National and Kapodistrian University of Athens
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
This is a contralateral, randomized, double-blind, placebo-controlled (HA) trial. One eye of each patient, randomly determined, will be assigned to receive artificial tears containing a combination of dexpanthenol-hyaluronic acid (study group) while the fellow eye will receive Placebo / identical combination containing the same ingredients and hyaluronic acid without dexpanthenol (control group). The drops will be applied hourly postoperatively, starting one hour after the surgery. The subject will participate in 1 preoperative visit, 1 postoperatively visit and following daily visits until complete reepithelialization of both eyes or day 7 postoperatively. Researchers will compare the epithelialization between the two eyes.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female subjects aged ≥ 18 * Bilateral trans PRK for the correction of myopia using the Schwind Amaris 1050RS laser at the same treatment zone (6.5mm) * Signed written informed consent Ability and willingness to participate in all examinations
Exclusion criteria
* Known hypersensitivity or intolerance to any component of the product * Previous refractive surgery * Myopic refractive error higher than 8.00 diopters (D) * Anisometropia higher than 2.00 D * Ocular or systemic disease that could affect epithelial healing
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to reepithelialization. | From the day of the surgery until complete reepithelialization of both eyes or day 7 postoperatively. | The primary endpoint is the time to reepithelialization. Slitlamp biomicroscopy will be preformed to evaluate the integrity of the corneal media and objectively assess epithelial healing with the use of fluoroscein staining. Α record of the time needed until no staining is present will be made. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Epithelial defect size in each visit | From the day of the surgery until complete reepithelialization of both eyes or day 7 postoperatively. | Epithelial defect size at each visit measured by slitlamp biomicroscopy The integrity of the corneal media is calculated from the remaining area (A) of the epithelial defects using the following equation: A=π {(α +b) /4}2 where a is the shortest dimension of the defect and b is the longest dimension. |
| Subjective evaluation of pain (discomfort) | From the day of the surgery until complete reepithelialization of both eyes or day 7 postoperatively. | Pain scores will be evaluated using a questionnaire on a scale of 0 to 4 as follows: * 0 as no discomfort or pain * 1 as mild discomfort * 2 as moderate burning pain * 3 as burning pain requiring oral medication (nimesulide 100 mg) * 4 as severe constant or sharp pain not mitigated with oral medication. |
| Subjective evaluation of vision | From the day of the surgery until complete reepithelialization of both eyes or day 7 postoperatively. | Uncorrected distance visual acuity measured using logMAR ETDRS charts at 4 m |
Countries
Greece
Contacts
Primary ContactMarios P Katsimpras, MD, MSc, PhDc
Outcome results
None listed